is a glp 1 insulin GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

The right choice depends on your other health conditions, insurance coverage, and tolerance which is exactly why this decision belongs with a rheumatologist, not a walk-in weight-loss clinic

In the context of AD, where neuroinflammation and neurotoxicity are prominent pathological hallmarks, the modus operandi of NLY01 offers a potential therapeutic avenue to mitigate analogous pathological mechanisms inherent to this neurodegenerative condition

Its Phase 3 weight-loss figures (in the low-to-mid 20% range) and its late-2025 FDA filing belong to the combination product, not to standalone cagrilintide, which remains at the Phase 2 stage with a peer-reviewed monotherapy result of about 10.8% at 26 weeks

Your surgical team should clear you before starting any GLP-1 therapy, typically waiting 612 months post-surgery to allow the stomach to fully adapt